In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

The detrimental effect of right atrial pacing on left atrial function and clinical outcome in cardiac resynchronization therapy.

Session Rapid Fire 5 - Non-pharmacological treatments: beyond conventional

Speaker Pieter Martens

Congress : Heart Failure 2019

  • Topic : heart failure
  • Sub-topic : Resynchronization Therapy
  • Session type : Rapid Fire Abstracts
  • FP Number : 1426

Authors : P Martens (Genk,BE), S Deferm (Genk,BE), M Dupont (Genk,BE), W Mullens (Genk,BE)

Authors:
P Martens1 , S Deferm1 , M Dupont1 , W Mullens1 , 1Hospital Oost-Limburg (ZOL), Cardiology - Genk - Belgium ,

Citation:

BACKGROUND
Data on the effects of right atrial (RA)-pacing on left atrial (LA) synchronicity, function and structure after cardiac resynchronization therapy (CRT) are scarce.

OBJECTIVE
To assess the impact of RA-pacing on LA-physiology and clinical outcome.

METHODS 
The effect of RA-pacing on LA-function, morphology and synchronicity was assessed in a prospective imaging cohort of HF-patients in sinus rhythm with guideline indication for CRT. Additionally in a retrospective outcome cohort of consecutive HF-patients undergoing CRT-implantation the relation of RA-pacing was assessed with various outcome endpoints. High versus low atrial pacing burden was defined as atrial pacing above or below 50% in both cohorts.

RESULTS
Thirty-six patients were included in the imaging cohort (age=68±11years). Six-months after CRT, patients with high RA-pacing burden showed less improvement in LA-maximum volume, minimum volume and total emptying-fraction (p<0.05). Peak atrial longitudinal strain, reservoir and booster strain-rate but not conduit strain-rate improved after CRT in patients with low RA-pacing burden and worsened in patients with high RA-pacing burden (p<0.05 for all). A high RA-pacing burden  induced significant intra-atrial dyssynchrony (maximum-opposing-wall-delay; 44±13msec vs 97±17msec, p=0.022) (see figure). A total of 569-patients were included in the outcome-cohort. After covariate adjustment, a high RA-pacing burden was associated with LV-reverse remodeling (ß=0.146,95%CI= [3.101;14.374],p=0.002), and new-onset or recurrence of atrial fibrillation (AF; 41% vs. 22% at median 31 [22-44] months follow-up; p<0.001). There was no difference in time to first HF-hospitalization or all-cause mortality (p=0.185) after covariate adjustment. However in a recurrent event analysis, heart failure readmission were more common in patients exposed to a high RA-pacing burden (p=0.002).

CONCLUSIONS 
RA-pacing in CRT patients negatively influences LA-morphology, function and synchronicity, which is associated with worse clinical outcome including diminished LV- reverse remodeling,  increased risk for new-onset or recurrent AF and heart failure readmission. Strategies reducing RA-pacing burden might be warranted.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are